242 related articles for article (PubMed ID: 27618657)
1. Efficacy of pancreatic exocrine replacement therapy for patients with unresectable pancreatic cancer in a randomized trial.
Woo SM; Joo J; Kim SY; Park SJ; Han SS; Kim TH; Koh YH; Chung SH; Kim YH; Moon H; Hong EK; Lee WJ
Pancreatology; 2016; 16(6):1099-1105. PubMed ID: 27618657
[TBL] [Abstract][Full Text] [Related]
2. Impact of the treatment of pancreatic exocrine insufficiency on survival of patients with unresectable pancreatic cancer: a retrospective analysis.
Domínguez-Muñoz JE; Nieto-Garcia L; López-Díaz J; Lariño-Noia J; Abdulkader I; Iglesias-Garcia J
BMC Cancer; 2018 May; 18(1):534. PubMed ID: 29728096
[TBL] [Abstract][Full Text] [Related]
3. A 6-month, open-label clinical trial of pancrelipase delayed-release capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery.
Gubergrits N; Malecka-Panas E; Lehman GA; Vasileva G; Shen Y; Sander-Struckmeier S; Caras S; Whitcomb DC
Aliment Pharmacol Ther; 2011 May; 33(10):1152-61. PubMed ID: 21418260
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of a new formulation of pancrelipase delayed-release capsules in children aged 7 to 11 years with exocrine pancreatic insufficiency and cystic fibrosis: a multicenter, randomized, double-blind, placebo-controlled, two-period crossover, superiority study.
Graff GR; Maguiness K; McNamara J; Morton R; Boyd D; Beckmann K; Bennett D
Clin Ther; 2010 Jan; 32(1):89-103. PubMed ID: 20171415
[TBL] [Abstract][Full Text] [Related]
5. Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: A double-blind randomized trial.
Whitcomb DC; Lehman GA; Vasileva G; Malecka-Panas E; Gubergrits N; Shen Y; Sander-Struckmeier S; Caras S
Am J Gastroenterol; 2010 Oct; 105(10):2276-86. PubMed ID: 20502447
[TBL] [Abstract][Full Text] [Related]
6. Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region.
Bruno MJ; Haverkort EB; Tijssen GP; Tytgat GN; van Leeuwen DJ
Gut; 1998 Jan; 42(1):92-6. PubMed ID: 9505892
[TBL] [Abstract][Full Text] [Related]
7. Exocrine pancreatic insufficiency following esophagectomy.
Huddy JR; Macharg FM; Lawn AM; Preston SR
Dis Esophagus; 2013 Aug; 26(6):594-7. PubMed ID: 23199208
[TBL] [Abstract][Full Text] [Related]
8. Randomised clinical trial: the efficacy and safety of pancreatin enteric-coated minimicrospheres (Creon 40000 MMS) in patients with pancreatic exocrine insufficiency due to chronic pancreatitis--a double-blind, placebo-controlled study.
Thorat V; Reddy N; Bhatia S; Bapaye A; Rajkumar JS; Kini DD; Kalla MM; Ramesh H
Aliment Pharmacol Ther; 2012 Sep; 36(5):426-36. PubMed ID: 22762290
[TBL] [Abstract][Full Text] [Related]
9. A Multicenter Open-Label Randomized Controlled Trial of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer.
Saito T; Nakai Y; Isayama H; Hirano K; Ishigaki K; Hakuta R; Takeda T; Saito K; Umefune G; Akiyama D; Watanabe T; Takagi K; Takahara N; Hamada T; Uchino R; Mizuno S; Mouri D; Yagioka H; Kogure H; Togawa O; Matsubara S; Ito Y; Yamamoto N; Tada M; Koike K
Pancreas; 2018 Aug; 47(7):800-806. PubMed ID: 29851751
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Pancrelipase/Pancreatin in Patients With Exocrine Pancreatic Insufficiency and a Medical History of Diabetes Mellitus.
Whitcomb DC; Bodhani A; Beckmann K; Sander-Struckmeier S; Liu S; Fuldeore M; Pollack PF; Khurmi RP
Pancreas; 2016; 45(5):679-86. PubMed ID: 26495784
[TBL] [Abstract][Full Text] [Related]
11. The Role of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer: A Prospective Cohort Study.
Saito T; Hirano K; Isayama H; Nakai Y; Saito K; Umefune G; Akiyama D; Watanabe T; Takagi K; Hamada T; Takahara N; Uchino R; Mizuno S; Kogure H; Matsubara S; Yamamoto N; Tada M; Koike K
Pancreas; 2017 Mar; 46(3):341-346. PubMed ID: 28099252
[TBL] [Abstract][Full Text] [Related]
12. CREON (Pancrelipase Delayed-Release Capsules) for the treatment of exocrine pancreatic insufficiency.
Kuhn RJ; Gelrud A; Munck A; Caras S
Adv Ther; 2010 Dec; 27(12):895-916. PubMed ID: 21086085
[TBL] [Abstract][Full Text] [Related]
13. Frequency of Appropriate Use of Pancreatic Enzyme Replacement Therapy and Symptomatic Response in Pancreatic Cancer Patients.
Barkin JA; Westermann A; Hoos W; Moravek C; Matrisian L; Wang H; Shemanski L; Barkin JS; Rahib L
Pancreas; 2019 Jul; 48(6):780-786. PubMed ID: 31210656
[TBL] [Abstract][Full Text] [Related]
14. The effect of oral pancreatic enzyme supplementation on the course and outcome of acute pancreatitis: a randomized, double-blind parallel-group study.
Kahl S; Schütte K; Glasbrenner B; Mayerle J; Simon P; Henniges F; Sander-Struckmeier S; Lerch MM; Malfertheiner P
JOP; 2014 Mar; 15(2):165-74. PubMed ID: 24618443
[TBL] [Abstract][Full Text] [Related]
15. Effects of Pancreatic Enzyme Replacement Therapy on Body Weight and Nutritional Assessments After Pancreatoduodenectomy in a Randomized Trial.
Kim H; Yoon YS; Han Y; Kwon W; Kim SW; Han HS; Yoon DS; Park JS; Park SJ; Han SS; Lee SE; Choi SH; Han IW; Kim E; Jang JY
Clin Gastroenterol Hepatol; 2020 Apr; 18(4):926-934.e4. PubMed ID: 31520730
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the efficacy and tolerance of pancrelipase and placebo in the treatment of steatorrhea in cystic fibrosis patients with clinical exocrine pancreatic insufficiency.
Stern RC; Eisenberg JD; Wagener JS; Ahrens R; Rock M; doPico G; Orenstein DM
Am J Gastroenterol; 2000 Aug; 95(8):1932-8. PubMed ID: 10950038
[TBL] [Abstract][Full Text] [Related]
17. Enzyme replacement improves survival among patients with pancreatic cancer: Results of a population based study.
Roberts KJ; Bannister CA; Schrem H
Pancreatology; 2019 Jan; 19(1):114-121. PubMed ID: 30385188
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of pancreatin minimicrospheres in patients with pancreatic exocrine insufficiency due to chronic pancreatitis.
Morawski JH; Prüfert A; van Engen A; Foerster D; Sander-Struckmeier S; Małecka-Panas E; Pezzilli R
J Med Econ; 2012; 15 Suppl 1():15-25. PubMed ID: 23043594
[TBL] [Abstract][Full Text] [Related]
19. Randomised clinical trial: a 1-week, double-blind, placebo-controlled study of pancreatin 25 000 Ph. Eur. minimicrospheres (Creon 25000 MMS) for pancreatic exocrine insufficiency after pancreatic surgery, with a 1-year open-label extension.
Seiler CM; Izbicki J; Varga-Szabó L; Czakó L; Fiók J; Sperti C; Lerch MM; Pezzilli R; Vasileva G; Pap A; Varga M; Friess H
Aliment Pharmacol Ther; 2013 Apr; 37(7):691-702. PubMed ID: 23383603
[TBL] [Abstract][Full Text] [Related]
20. A 51-week, open-label clinical trial in India to assess the efficacy and safety of pancreatin 40000 enteric-coated minimicrospheres in patients with pancreatic exocrine insufficiency due to chronic pancreatitis.
Ramesh H; Reddy N; Bhatia S; Rajkumar JS; Bapaye A; Kini D; Kalla M; Thorat V
Pancreatology; 2013; 13(2):133-9. PubMed ID: 23561971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
